Survey of Paediatric Oncologists and Pathologists regarding Their Views and Experiences with Variant Translocations in Ewing and Ewing-Like Sarcoma: A Report of the Children’s Oncology Group

Figure 3

Perceptions of respondents on the optimal stratification of variant chromosomal translocations on future Ewing sarcoma clinical trials. The data represent the percentage of respondents who believed that a given translocation in the column on the left should result in inclusion in a Ewing sarcoma clinical trial in the primary stratum (blue bar and percentage), in a separate stratum (orange bar and percentage) or if the translocation makes a patient ineligible (red bar and percentage) for a Ewing sarcoma study. The teal bar and percentage indicate the number of respondents who were unsure of how the translocation should influence inclusion criteria.